Biosimilar Litigation: Celltrion, Pfizer Claim Victory On Janssen’s Remaining Infringement Claim
You may also be interested in...
Pfizer would still be at risk for damages from biosimilar launch if Janssen's manufacturing process patent is upheld even as US Federal Circuit affirms that patent covering Remicade's active ingredient is invalid.
Pfizer's suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any of Pfizer's biosimilar Inflectra is reimbursed, but J&J says Pfizer has failed to show the value of Inflectra.
The company is on track to launch the first Remicade biosimilar in the US Nov. 21 using dedicated sales reps and resources from the innovative side of the business, though it will not be a traditional sales force.